22
“Cancer Trends Demand Call To Action” The Tipping Point “At Memorial Sloan-Kettering Cancer Center, we recently made a decision that should have been a no-brainer: we are not going to give a phenomenally expensive new cancer drug to our patients” Zaltrap v. Avastin –Same Efficacy –$11,000 difference Cost Trends

23
More than 90 percent of cancer therapies approved in the last five years cost more than $20,000 for a 12- week course of therapy. Significant price increases in oncology products have not necessarily shown a correlation between overall survival or progression free survival.

34
Adherence rates across conditions * 1 year after initiation of both antihypertensive and lipid-lowering therapies; proportion of days covered ≥80%. † 1 year after initiation of therapy; medication possession ration (MPR) ≥80%. ‡ MPR 80%-110% of days eligible for Medi- Cal. § MPR >80% for patients with at least 90 days of observation.